Apropos Red's last post, I am still unclear how much IP for MANF the company really has. Does all this research being done everywhere have to ultimately licence from AMBS before marketing? Or is it only certain types of treatments? Only in the US? If there is some report with clarification of this (or someone just understands better than me) I would so appreciate an explanation.

Best of luck to all of us longs on this (hopefully) pivotal week

Here's to some good news tomorrow morning!